These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38613911)
1. Treatment of patients with BRAF Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911 [TBL] [Abstract][Full Text] [Related]
2. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation. Al-Salama ZT Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242 [TBL] [Abstract][Full Text] [Related]
3. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748 [TBL] [Abstract][Full Text] [Related]
4. Retrospective Analysis of Treatment Pathways in Patients With BRAF Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968 [TBL] [Abstract][Full Text] [Related]
5. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. Hafliger E; Boccaccino A; Lapeyre-Prost A; Perret A; Gallois C; Antista M; Pilla L; Lecomte T; Scartozzi M; Soularue E; Salvatore L; Bourgeois V; Salati M; Tougeron D; Evesque L; Vaillant JN; El-Khoury R; Lonardi S; Cremolini C; Taieb J Eur J Cancer; 2022 Jun; 168():34-40. PubMed ID: 35436675 [TBL] [Abstract][Full Text] [Related]
6. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF Kotani D; Takashima A; Kato T; Satoh T; Masuishi T; Komatsu Y; Shiozawa M; Esaki T; Izawa N; Takeuchi S; Bando H; Iwasa S; Hasegawa H; Yamaguchi T; Taniguchi H; Ushida Y; Oizaki T; Inoue C; Yoshino T Clin Colorectal Cancer; 2024 Jun; 23(2):174-182.e6. PubMed ID: 38553360 [TBL] [Abstract][Full Text] [Related]
8. Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab. Zwart K; van Nassau SCMW; van der Baan FH; Koopman M; Snaebjornsson P; van Gestel AJ; Vink GR; Roodhart JML Br J Cancer; 2024 Jul; 131(1):110-116. PubMed ID: 38769450 [TBL] [Abstract][Full Text] [Related]
12. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847 [TBL] [Abstract][Full Text] [Related]
13. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039 [TBL] [Abstract][Full Text] [Related]
15. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. Kotani D; Bando H; Taniguchi H; Masuishi T; Komatsu Y; Yamaguchi K; Nakajima T; Satoh T; Nishina T; Esaki T; Nomura S; Takahashi K; Iida S; Matsuda S; Motonaga S; Fuse N; Sato A; Fujii S; Ohtsu A; Ebi H; Yoshino T ESMO Open; 2020; 5(1):e000624. PubMed ID: 33551068 [TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. Li S; Hu H; Ding D; Zhu Y; Huang J Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738 [TBL] [Abstract][Full Text] [Related]